CELGZ Projected Dividend Yield
Contingent Value Rt/Celgene Corp ( NASDAQ : CELGZ )Celgene is a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Co.'s primary commercial stage products include: REVLIMID®, an oral immunomodulatory drug; POMALYST®/IMNOVID®, a proprietary, small molecule; OTEZLA®, an oral small-molecule inhibitor of phosphodiesterase 4 for cyclic adenosine monophosphate; ABRAXANE®, a solvent-free chemotherapy product; and VIDAZA®, a pyrimidine nucleoside analog. In addition, Co. provides other product sales and licensing arrangements. 21 YEAR PERFORMANCE RESULTS |
CELGZ Dividend History Detail CELGZ Dividend News CELGZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2019 |
N/A |
Mar 21, 2019 |
Mar 23, 2019 |
Mar 25, 2019 |
0.0359 |
2019 Total: |
0.0359 |